NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The business earned $1.18 million during the quarter, compared to the consensus estimate of $2.92 million. Kala Pharmaceuticals had a negative return on equity of 173.83% and a negative net margin of 1,553.29%. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Kala Pharmaceuticals.

5 analysts have issued 1-year price targets for Kala Pharmaceuticals' stock. Their forecasts range from $6.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $18.20 in the next year. This suggests a possible upside of 185.9% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Media coverage about KALA stock has trended positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,240,000 shares, an increase of 11.5% from the January 15th total of 4,700,000 shares. Based on an average trading volume of 545,600 shares, the short-interest ratio is currently 9.6 days. Currently, 19.4% of the shares of the company are short sold. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Achillion Pharmaceuticals (ACHN), Radius Health (RDUS), Cytokinetics (CYTK), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Applied Therapeutics (APLT), Endonovo Therapeutics (ENDV), ImmunoGen (IMGN), Homology Medicines (FIXX), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), CannTrust (CNTTF) and ANI Pharmaceuticals (ANIP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), Amarin (AMRN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX) and REDHILL BIOPHAR/S (RDHL).

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Banco Bilbao Vizcaya Argentaria S.A. (4.06%), Sofinnova Investments Inc. (1.92%), Polaris Venture Management Co. V L.L.C. (1.64%), Alyeska Investment Group L.P. (1.27%), State Street Corp (1.05%) and Geode Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Bank of America Corp DE, Alambic Investment Management L.P. and Group One Trading L.P.. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was bought by a variety of institutional investors in the last quarter, including Banco Bilbao Vizcaya Argentaria S.A., Sofinnova Investments Inc., Wedbush Securities Inc., State Street Corp, Alyeska Investment Group L.P., Geode Capital Management LLC, Virtu Financial LLC and UBS Group AG. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $6.37.

Kala Pharmaceuticals has a market capitalization of $234.23 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]